Inclusion Criteria:  Patients with age between 18 and 65 years; hematopoietic stem cell transplantation for the first time; Lymphoma patients with the requirement for autologous; ECOG score ≤2; Estimated survival time > 3 months; All acute toxicity caused by previous chemotherapy or treatment has been restored; 7.1) The absolute value of neutrophils (>1.5×10^9/L); Hemoglobin (> 90 g/L); 2)Upper Limit Normal (ULN) or creatinine clearance rate (>40 mL/min) of serum creatinine (<1.5 times normal value upper limit) (estimated by Cockcroft-Gault formula); Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) = 2.5 times ULN; 7) Coagulation function: International Normalized Ratio (INR) = 1.5 times ULN; Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) = 1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are using anticoagulant therapy at screening time). Within the expected range; Thyrotropin (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) were all within the normal range (+10%);  8.Not in pregnancy; 9.Written informed consent are acquired.  Exclusion Criteria:  Had received autologous hematopoietic stem cell transplantation or allogeneic transplantation; bone marrow involvement; Patients with active autoimmune diseases requiring systematic treatment were excluded according to the clinical judgment of the investigators; Patients with active infections requiring systematic treatment were excluded according to the clinical judgment of the investigators; Serious complications, such as severe infection, heart, lung, liver and kidney dysfunction； patients in fever of unknown origin before medication（>38℃）； central nervous system involvement; Patients that received pelvic radiotherapy; patients will received Chemotherapy or radiotherapy under the diaphragm after transplantation ； Participation or consideration of participation in another biomedical study during the follow-up period of the present trial; Pregnant or lactating women; Serious heart, lung, hemorrhagic disease; Past psychiatric history; incapacitated or restricted; patient's condition increase the risk of receiving the drug treatment or confusion about the toxic reaction； Severe intolerance to the growth factor under study, or hypersensitivity to one of their components; the patients did not comply with the study; Other situation that investigators consider as contra-indication for this study.